- Home
- BCLI vs AYTU Comparison
BCLI vs AYTU Comparison
Compare BCLI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- AYTU
- Stock Information
- Founded
- BCLI 2000
- AYTU N/A
- Country
- BCLI United States
- AYTU United States
- Employees
- BCLI N/A
- AYTU N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- AYTU Health Care
- Exchange
- BCLI Nasdaq
- AYTU Nasdaq
- Market Cap
- BCLI 9.9M
- AYTU 8.3M
- IPO Year
- BCLI N/A
- AYTU N/A
- Fundamental
- Price
- BCLI $1.21
- AYTU $1.15
- Analyst Decision
- BCLI Strong Buy
- AYTU
- Analyst Count
- BCLI 1
- AYTU 0
- Target Price
- BCLI $30.00
- AYTU N/A
- AVG Volume (30 Days)
- BCLI 35.3K
- AYTU 37.1K
- Earning Date
- BCLI 03-31-2025
- AYTU 05-14-2025
- Dividend Yield
- BCLI N/A
- AYTU N/A
- EPS Growth
- BCLI N/A
- AYTU N/A
- EPS
- BCLI N/A
- AYTU N/A
- Revenue
- BCLI N/A
- AYTU $77,232,000.00
- Revenue This Year
- BCLI $170.09
- AYTU N/A
- Revenue Next Year
- BCLI N/A
- AYTU $8.14
- P/E Ratio
- BCLI N/A
- AYTU N/A
- Revenue Growth
- BCLI N/A
- AYTU N/A
- 52 Week Low
- BCLI $1.05
- AYTU $1.15
- 52 Week High
- BCLI $11.25
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- BCLI 30.68
- AYTU 33.76
- Support Level
- BCLI $1.12
- AYTU $1.20
- Resistance Level
- BCLI $1.59
- AYTU $1.29
- Average True Range (ATR)
- BCLI 0.11
- AYTU 0.06
- MACD
- BCLI -0.02
- AYTU 0.00
- Stochastic Oscillator
- BCLI 17.31
- AYTU 0.00
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.